Published in Acta Neuropathol on January 01, 1991
A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure. J Exp Med (1993) 2.29
A somatically mutated human antiganglioside IgM antibody that induces experimental neuropathy in mice is encoded by the variable region heavy chain gene, V1-18. J Clin Invest (1996) 1.74
Guillain-Barré syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM1 and anti-GQ1b Antibodies in rabbits. Infect Immun (2001) 1.03
Experimental immunization with Borrelia burgdorferi induces development of antibodies to gangliosides. Infect Immun (1995) 1.00
Autoantibodies to brain components and antibodies to Acinetobacter calcoaceticus are present in bovine spongiform encephalopathy. Infect Immun (1999) 0.91
Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey. Proc Jpn Acad Ser B Phys Biol Sci (2012) 0.90
Expression of human immunodeficiency virus type 1 in the nervous system of transgenic mice leads to neurological disease. J Virol (1994) 0.89
Lewis rats immunized with GM1 ganglioside do not develop peripheral neuropathy. J Neuroimmunol (2007) 0.79
Anti-GM1 antibodies in polyneuropathies of unknown origin. J Clin Pathol (1996) 0.78
IgM deposits at nodes of Ranvier in a patient with amyotrophic lateral sclerosis, anti-GM1 antibodies, and multifocal motor conduction block. Ann Neurol (1990) 2.67
A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol (1988) 2.12
The spectrum of neurologic disease associated with anti-GM1 antibodies. Neurology (1990) 1.87
Antibodies to GM1 and GD1b in patients with motor neuron disease without plasma cell dyscrasia. Ann Neurol (1989) 1.55
Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies. Ann Neurol (1990) 1.21
A syndrome of asymmetric limb weakness with motor conduction block. Neurology (1990) 1.08
Monoclonal IgM with unique specificity to gangliosides GM1 and GD1b and to lacto-N-tetraose associated with human motor neuron disease. Neurology (1988) 1.06
Ganglioside GM1, a molecular target for immunological and toxic attacks: similarity of neuropathological lesions induced by ganglioside-antiserum and cholera toxin. Acta Neuropathol (1986) 1.03
Natural autoantibodies constitute a substantial part of normal circulating immunoglobulins. Ann N Y Acad Sci (1986) 1.03
Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease. Neurology (1986) 1.03
Antisera to different glycolipids induce myelin alterations in mouse spinal cord tissue cultures. Brain Res (1985) 0.97
Lower motor neuron disease in a patient with autoantibodies against Gal(beta 1-3)GalNAc in gangliosides GM1 and GD1b: improvement following immunotherapy. Neurology (1990) 0.91
Sprouting from chicken embryo dorsal root ganglia induced by nerve growth factor is specifically inhibited by affinity-purified antiganglioside antibodies. Proc Natl Acad Sci U S A (1982) 0.90
Motor neuron syndrome and monoclonal IgM with antibody activity against gangliosides GM1 and GD1b. Ann Neurol (1988) 0.90
Immunofluorescence study of patients with neuropathy and IgM M proteins. Ann Neurol (1985) 0.89
Specific modulation of sodium channels in mammalian nerve by monoclonal antibodies. Proc Natl Acad Sci U S A (1986) 0.88
Conduction velocity and conduction block after experimental ischaemic nerve injury. J Neurol Sci (1982) 0.87
Monoclonal IgMs with anti-Gal(beta 1-3) GalNAc activity in lower motor neuron disease; identification of glycoprotein antigens in neural tissue and cross-reactivity with serum immunoglobulins. J Neuroimmunol (1989) 0.86
Ganglioside syndrome, a new autoimmune neurologic disorder, experimentally induced with brain gangliosides. Neurosci Lett (1976) 0.86
Anti-GM1 ganglioside antibodies with differing fine specificities in patients with multifocal motor neuropathy. J Neuroimmunol (1989) 0.85
Ganglioside localization on myelinated nerve fibres by cholera toxin binding. J Neurocytol (1983) 0.84
Identification and characterization of gangliosides reacting with IgM paraproteins in three patients with neuropathy associated with biclonal gammopathy. J Neurochem (1988) 0.84
Antibodies to gangliosides inhibit goldfish optic nerve regeneration in vivo. J Neurosci Res (1984) 0.83
Changes in the sciatic nerve of the rabbit and its tissue constituents during development. J Neurochem (1974) 0.81
Peanut agglutinin receptor is a marker of myelin in rat brain. Developmental changes in its distribution. J Neurochem (1986) 0.81
Human monoclonal IgM anti-Gal(beta 1-3)GalNAc autoantibodies bind to the surface of bovine spinal motoneurons. J Neuropathol Exp Neurol (1990) 0.80
Abnormal maturation of cerebral cortex and behavioral deficit in adult rats after neonatal administration of antibodies to ganglioside. Brain Res (1981) 0.80
Histochemical localization of galactose-containing glycoconjugate at peripheral nodes of Ranvier in the rat. J Histochem Cytochem (1985) 0.79
Gangliosides of the peripheral nervous system of the rat. Life Sci (1975) 0.79
Monoclonal IgM in two patients with motor neuron disease bind to the carbohydrate antigens Gal(beta 1-3)GalNAc and Gal(beta 1-3)GlcNAc. J Neuroimmunol (1988) 0.79
Motor dominant neuropathy and IgM paraproteinemia: the IgM M-protein binds to specific gangliosides. J Neuroimmunol (1989) 0.79
Generation of antibodies to gangliosides GM1 and GD1b. Genetic control of fine antigenic specificity. Ann N Y Acad Sci (1988) 0.78
Sphinolipids of human skeletal muscle. Biochim Biophys Acta (1972) 0.77
Localization of neural epitopes that bind to IgM monoclonal autoantibodies (M-proteins) from two patients with motor neuron disease. J Neuroimmunol (1989) 0.77
Regenerative capacity of the goldfish visual system is affected by antibodies specific to gangliosides injected intraocularly. J Neuroimmunol (1984) 0.77
MicroRNA deregulation in human thyroid papillary carcinomas. Endocr Relat Cancer (2006) 4.11
PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell (1990) 3.98
Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. Cell (1988) 3.57
Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene (2007) 3.29
Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell (1988) 2.94
Calorimetric determination of the enthalpy change for the alpha-helix to coil transition of an alanine peptide in water. Proc Natl Acad Sci U S A (1991) 2.84
IgM deposits at nodes of Ranvier in a patient with amyotrophic lateral sclerosis, anti-GM1 antibodies, and multifocal motor conduction block. Ann Neurol (1990) 2.67
Primary lateral sclerosis. A clinical diagnosis reemerges. Arch Neurol (1988) 2.62
A new oncogene in human thyroid papillary carcinomas and their lymph-nodal metastases. Nature (1987) 2.60
The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res (1999) 2.56
Crystal chemistry of the 4,4'-dimethyl-2,2'bipyridine/copper bromide system. Inorg Chem (2001) 2.56
Electrophysiological findings in entrapment of the median nerve at wrist and elbow. J Neurol Neurosurg Psychiatry (1974) 2.54
The natural history of primary lateral sclerosis. Neurology (2006) 2.31
Inhibition of HMGI-C protein synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol (1995) 2.22
Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope (1997) 2.15
Neurolymphomatosis: a clinicopathologic syndrome re-emerges. Neurology (1992) 2.14
High level expression of the HMGI (Y) gene during embryonic development. Oncogene (1996) 2.13
Objective tests for upper motor neuron involvement in amyotrophic lateral sclerosis (ALS). Neurology (2004) 2.09
RON is a heterodimeric tyrosine kinase receptor activated by the HGF homologue MSP. EMBO J (1994) 2.04
Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): clinical, biochemical, and genetic features of an autosomal recessive mitochondrial disorder. Neurology (1994) 2.00
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res (1998) 2.00
High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene (1989) 1.94
Multifocal motor neuropathy with conduction block: is it a distinct clinical entity? Neurology (1992) 1.93
The spectrum of neurologic disease associated with anti-GM1 antibodies. Neurology (1990) 1.87
Structural abnormalities of subicular dendrites in subjects with schizophrenia and mood disorders: preliminary findings. Arch Gen Psychiatry (2000) 1.82
Benign infantile mitochondrial myopathy due to reversible cytochrome c oxidase deficiency. Ann Neurol (1983) 1.82
Respiratory distress as the initial manifestation of Werdnig-Hoffmann disease. Pediatrics (1974) 1.76
Peripheral neuropathy in patients with inflammatory bowel disease. Brain (2005) 1.75
Myelin-associated glycoprotein is the antigen for a monoclonal IgM in polyneuropathy. J Neurochem (1982) 1.75
Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies. Muscle Nerve (1996) 1.69
The RET receptor: function in development and dysfunction in congenital malformation. Trends Genet (2001) 1.67
Vertical optic disk diameter: discrepancy between planimetric and SLO measurements. Invest Ophthalmol Vis Sci (1995) 1.66
Quantitative objective markers for upper and lower motor neuron dysfunction in ALS. Neurology (2007) 1.63
The expression of the high mobility group HMGI (Y) proteins correlates with the malignant phenotype of human thyroid neoplasias. Oncogene (1995) 1.61
Motor neuron disease and amyotrophic lateral sclerosis: relation of high CSF protein content to paraproteinemia and clinical syndromes. Neurology (1990) 1.61
Onset of natural killer cell lymphomas in transgenic mice carrying a truncated HMGI-C gene by the chronic stimulation of the IL-2 and IL-15 pathway. Proc Natl Acad Sci U S A (2001) 1.60
Lymphoma, motor neuron diseases, and amyotrophic lateral sclerosis. Ann Neurol (1991) 1.60
Acute quadriplegic myopathy: a complication of treatment with steroids, nondepolarizing blocking agents, or both. Neurology (1992) 1.58
Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression. Oncogene (1997) 1.57
Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med (1979) 1.57
Increased expression of the pro-inflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann Neurol (2001) 1.55
Lymphoproliferative disorders and motor neuron disease: an update. Neurology (1997) 1.54
Plasma-cell dyscrasia and peripheral neuropathy with a monoclonal antibody to peripheral-nerve myelin. N Engl J Med (1980) 1.54
Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene (1998) 1.52
Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J (1997) 1.51
Polyglucosan body disease. Muscle Nerve (1991) 1.50
Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC. Proc Natl Acad Sci U S A (1992) 1.46
Vigorimeter grip strength in CIDP: a responsive tool that rapidly measures the effect of IVIG--the ICE study. Eur J Neurol (2012) 1.45
Autopsy-proven amyotrophic lateral sclerosis, Waldenström's macroglobulinemia, and antibodies to sulfated glucuronic acid paragloboside. Neurology (1995) 1.44
Unusual manifestations of Epstein-Barr virus encephalomyelitis. Infection (1990) 1.42
Progressive multifocal leukoencephalopathy in a male homosexual with T-cell immune deficiency. N Engl J Med (1982) 1.41
Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res (1996) 1.37
Fibrillary astrocytes proliferate in response to brain injury: a study combining immunoperoxidase technique for glial fibrillary acidic protein and radioautography of tritiated thymidine. Dev Biol (1979) 1.37
High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J Clin Endocrinol Metab (1999) 1.37
Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci (2001) 1.35
Motor and sensory conduction in different segments of the radial nerve in normal subjects. J Neurol Neurosurg Psychiatry (1969) 1.32
Celiac neuropathy. Neurology (2003) 1.31
Specificity of mouse and human monoclonal antibodies to myelin-associated glycoprotein. Neurology (1984) 1.30
Description of a human papillary thyroid carcinoma cell line. Morphologic study and expression of tumoral markers. Cancer (1994) 1.30
Characterization of sulfated glucuronic acid containing glycolipids reacting with IgM M-proteins in patients with neuropathy. J Biol Chem (1987) 1.30
Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res (1998) 1.29
Docking protein FRS2 links the protein tyrosine kinase RET and its oncogenic forms with the mitogen-activated protein kinase signaling cascade. Mol Cell Biol (2001) 1.29
The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res (1998) 1.27
Critical role of the HMGI(Y) proteins in adipocytic cell growth and differentiation. Mol Cell Biol (2001) 1.26
XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway. Oncogene (2008) 1.25
Rat protein tyrosine phosphatase eta suppresses the neoplastic phenotype of retrovirally transformed thyroid cells through the stabilization of p27(Kip1). Mol Cell Biol (2000) 1.24
Experimental conduction block induced by serum from a patient with anti-GM1 antibodies. Ann Neurol (1992) 1.23
Rate of recovery in motor and sensory fibres of the radial nerve: clinical and electrophysiological aspects. J Neurol Neurosurg Psychiatry (1970) 1.22
Metastatic carcinoma to the pituitary gland. Br J Neurosurg (1989) 1.22
Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res (1994) 1.22
Muscle rearrangement in patients with hemiparesis after stroke: an electrophysiological and morphological study. Eur Neurol (1993) 1.21
Visual, auditory and somatosensory pathway involvement in hereditary cerebellar ataxia, Friedreich's ataxia and familial spastic paraplegia. Electroencephalogr Clin Neurophysiol (1981) 1.21
Clinical syndromes associated with ragged red fibers. Rev Neurol (Paris) (1991) 1.20
A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. Cell Death Differ (2011) 1.19
Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle Nerve (2009) 1.19
RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene (1995) 1.19
Normal and dystrophin-deficient muscle fibers in carriers of the gene for Duchenne muscular dystrophy. Am J Pathol (1988) 1.18
RET/PTC activation in hyalinizing trabecular tumors of the thyroid. Am J Surg Pathol (2000) 1.17